Company Overview
Boehringer Ingelheim is a leading global pharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885, this family-owned company operates with a strong commitment to innovative research and high-quality products. Its primary focus is on developing medicines that improve the health and quality of life for humans and animals alike.
Boehringer Ingelheim's research and development efforts span several therapeutic areas, including human pharmaceuticals, animal health, and biosimilars. The company invests significantly in R&D to discover new solutions for diseases that lack effective treatment options, ensuring it remains at the forefront of scientific advancements.
The company’s portfolio includes products for diseases such as respiratory conditions, cardiovascular health, and diabetes. Furthermore, its animal health division offers veterinary medicines, vaccines, and feed additives to enhance animal protection and welfare. This diverse range of products underscores Boehringer Ingelheim’s dedication to addressing pressing health challenges worldwide.
With a strong emphasis on innovation and collaboration, Boehringer Ingelheim partners with academic institutions, biotechnology companies, and other organizations to accelerate the development of novel therapies. This collaborative approach empowers researchers to leverage collective expertise and resources, driving progress in medical science.
Boehringer Ingelheim is also committed to sustainability and ethical practices. The company’s initiatives prioritize environmental stewardship, compliance with regulatory standards, and a dedication to improving global health outcomes. By aligning its business strategies with these values, it aims to create lasting positive impacts on communities around the world.